NEW YORK (GenomeWeb News) – OncoMed Pharmaceuticals and Fluidigm have entered into a collaboration to use microfluidic tools to analyze the heterogeneity of tumor cells, including cancer stem cells, the companies said yesterday.

The partnership will combine Fluidigm's microfluidic platforms with OncoMed's cancer stem cell sorting technology to generate tools to analyze, quantify and develop treatments directed at a highly tumorigenic cell population, the companies said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.